DB
IMVT icon

Dmitry Balyasny’s Immunovant IMVT Stock Holding History

Dmitry Balyasny’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-448,051
Closed -$7.22M – 3306
2025
Q3 		$7.22M Buy
448,051
+250,482
+127% +$4.06M 0.01% 1205
2025
Q2 		$3.16M Buy
+197,569
New +$2.99M ﹤0.01% 1513
2024
Q1 		– Sell
-9,783
Closed -$412K – 2845
2023
Q4 		$412K Buy
+9,783
New +$360K ﹤0.01% 2026
2023
Q3 		– Sell
-255,677
Closed -$5.78M – 2483
2023
Q2 		$4.85M Buy
+255,677
New +$4.77M 0.01% 1076
2023
Q1 		– Sell
-375,775
Closed -$6.67M – 2890
2022
Q4 		$6.67M Buy
375,775
+222,272
+145% +$2.8M 0.02% 906
2022
Q3 		$857K Buy
+153,503
New +$750K ﹤0.01% 1865
2022
Q2 		– Sell
-14,616
Closed -$81K – 2945
2022
Q1 		$81K Buy
+14,616
New +$91K ﹤0.01% 2172
2021
Q1 		– Sell
-59,974
Closed -$2.77M – 1908
2020
Q4 		$2.77M Buy
+59,974
New +$2.77M 0.02% 801

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Dmitry Balyasny's IMVT Position: Q4 2025 in Review

Dmitry Balyasny sold out of Immunovant (IMVT) in Q4 2025, closing a stake of 448,051 shares — an estimated $7.22M sold.

Dmitry Balyasny first reported a position in IMVT in Q4 2020 and held it in 8 quarters. The position peaked at $7.22M in Q3 2025. 196 funds tracked by Wall St. Rank hold IMVT as of Q4 2025.

  • Dmitry Balyasny reported no remaining Immunovant position as of Q4 2025 after selling out during the quarter.
  • Dmitry Balyasny sold 448,051 Immunovant shares in Q4 2025, an estimated $7.22M.
  • Dmitry Balyasny first reported a position in Immunovant in Q4 2020 and held it in 8 quarters.
  • Dmitry Balyasny's Immunovant position peaked at $7.22M in Q3 2025.
  • 196 funds tracked by Wall St. Rank held Immunovant as of Q4 2025.

Based on Balyasny Asset Management's 13F filing for Q4 2025, filed 17 Feb 2026.